The NHS is launching a significant new treatment option for patients in England living with drug-resistant HIV. While most people with the virus manage their health through standard daily medications, a minority faces mutations that render those options ineffective. Lenacapavir serves as a vital intervention for these individuals.
Approximately 92 patients are eligible for the treatment in the initial rollout, a number expected to grow to 300 within the next three years. Patients receive an initial two-day course of tablets followed by injections administered every six months. This approach aims to reduce viral loads to undetectable levels for those who previously had few alternatives.
One patient, who has lived with the virus since birth, reports that the drug changed her life after she struggled with traditional pills and suffered from a weakened immune system. Health officials noted that the goal remains to stop new HIV transmissions by 2030, and this development marks progress toward ensuring no one dies from AIDS-related conditions in the UK.
Leaders from national health organizations described the move as a major step forward for those who have exhausted other options. By providing a reliable injectable method, the NHS provides a path toward long-term stability and health for a group that historically faced limited medical choices.